Hosted on MSN6d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Medical News Today11d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Inquirer on MSN2d
World’s first anti-depression nasal spray receives FDA approval
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
Verywell Health on MSN9d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Medindia10d
FDA Approves Esketamine Nasal Spray for Resistant Depression
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Fast Company on MSN15d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
Popular Science16d
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a ...
Healio15d
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson ...
Medscape13d
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Medical Xpress16d
FDA approves nasal spray for treatment-resistant depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
AOL11d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... communities about the difference between esketamine versus ketamine, and whether esketamine ...